GT Biopharma Reports Third Quarter 2023 Financial Results
November 01, 2023 09:00 ET
|
GT Biopharma, Inc.
IND submission for GTB-3650, 2nd generation nanobody TriKE® for treatment of CD33+ leukemia, expected in Q4 2023Phase 1 clinical trial initiation evaluating GTB-3650 for treatment of CD33+ leukemia...